INSTYTUT PSYCHIATRII I NEUROLOGII

Their core work

The Institute of Psychiatry and Neurology (IPiN) in Warsaw is Poland's primary national clinical and research institution for neurological and psychiatric conditions. Their H2020 participation reveals a role as a clinical trial site and outcomes research contributor, bringing patient cohorts, neurological expertise, and research infrastructure to large multi-centre European consortia. In PRECIOUS, they contributed to a randomised clinical trial targeting complication prevention in elderly stroke patients. In IDEA-FAST, they are advancing the development and validation of digital endpoints to measure fatigue, sleep disturbance, and daily functioning in patients with neurodegenerative and immune-mediated inflammatory disorders.

What they specialise in

How they've shifted over time

In the earlier period (from 2015), IPiN's focus was squarely on acute stroke care — specifically the prevention of post-stroke complications in elderly patients through rigorous randomised trials, with functional outcome as the primary measure. By 2019, their focus shifted toward chronic neurological conditions and the measurement challenge they pose: how to capture fatigue, sleep disruption, and daily functioning using digital tools rather than clinical visits. The direction of travel is clear — from acute intervention trials toward chronic disease digital monitoring, reflecting broader trends in European neurology research toward decentralised, data-driven patient follow-up.

IPiN is moving toward digital and remote patient monitoring in chronic neurological conditions, making them a relevant partner for any consortium working on wearable health technology, digital biomarkers, or real-world evidence in neurology or psychiatry.

How they like to work

IPiN participates exclusively as a consortium partner and has never served as a project coordinator in H2020, indicating they operate as a specialist contributor rather than a research driver. Despite only two projects, they engaged with 74 unique partners across 18 countries — a scale typical of major multi-centre clinical trials where each site contributes patient access and protocol adherence rather than scientific leadership. This pattern suggests they are valued for their clinical infrastructure and patient cohort access, and are most useful to consortia that need a credible Eastern European neurology site.

74 unique consortium partners across 18 countries from just two projects — an unusually broad network footprint that reflects participation in large, coordinated European clinical trial consortia. No geographic concentration is visible; the breadth suggests involvement driven by project topic rather than national or regional loyalty.

What sets them apart

As Poland's national institute of psychiatry and neurology, IPiN offers something few Central and Eastern European institutions can match for European consortia: both clinical trial infrastructure and access to patient populations in a large EU member state. Their combination of traditional RCT experience (PRECIOUS) and active engagement with digital endpoints (IDEA-FAST) positions them at the boundary between established clinical practice and next-generation outcome science. For a consortium needing a credible neurological clinical site in Poland, they are the default first call.

Highlights from their portfolio

• PRECIOUS
  The largest-funded project (EUR 208,100), running seven years to 2022, positioned IPiN within a multi-country RCT on one of the highest-burden neurological events in elderly populations — acute stroke.
• IDEA-FAST
  Running until 2026 with a forward-looking scope, this project places IPiN at the intersection of digital health technology and neurodegenerative disease, covering immune-mediated conditions alongside classical neurodegeneration.